Yoshihiko Kiyasu

Yoshihiko Kiyasu

Auto-generated profile, based on publicly available information

Yoshihiko Kiyasu

Department of Infectious Diseases, University of Tsukuba Hospital, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYoshihiko Kiyasu
Yoshihiko Kiyasu
SHShigemi Hitomi
Shigemi Hitomi
YFYasunori Funayama
Yasunori Funayama
KSKazuhito Saito
Kazuhito Saito
HIHiroichi Ishikawa
Hiroichi Ishikawa

7 March 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
YTYuto Takeuchi
Yuto Takeuchi
YAYusaku Akashi
Yusaku Akashi
YKYoshihiko Kiyasu
Yoshihiko Kiyasu
NTNorihiko Terada
Norihiko Terada
YKYoko Kurihara
Yoko Kurihara
HSHiromichi Suzuki
Hiromichi Suzuki
Since respiratory sample collection is an uncomfortable experience, simultaneous detection of pathogens with a single swab is preferable. We prospectively evaluated the clinical performance of a newly developed antigen test QuickNavi-Flu+COVID19 Ag (Denka Co., Ltd., Tokyo, Japan) which can detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses at the same time with a single testing device. We included those who were suspected of contracting coronavirus disease 2019 (COVID-19) and were referred to a PCR center at Ibaraki prefecture in Japan, between August 2, 2021 to September 13, 2021, when the variant carrying L452R spike mutation of SARS-CoV-2 were prevalent. Additional nasopharyngeal samples and anterior nasal samples were obtained for the antigen test and were compared with a reference real-time reverse transcription PCR (RT-PCR) using nasopharyngeal samples. In total, 1510 nasopharyngeal samples and 862 anterior nasal samples were evaluated. During the study period, influenza viruses were not detected by QuickNavi-Flu+COVID19 Ag and reference real-time RT-PCR. For SARS-CoV-2 detection in nasopharyngeal samples, the sensitivity and specificity of the antigen test were 80.9% and 99.8%, respectively. The sensitivity and specificity using anterior nasal samples were 67.8% and 100%, respectively. In symptomatic cases, the sensitivities increased to 88.3% with nasopharyngeal samples and 73.7% with anterior nasal samples. There were three cases of discrepant results between the antigen test and the real-time RT-PCR. All of them were positive with the antigen test but negative with the real-time RT-PCR in SARS-CoV-2 detection. A combo kit, QuickNavi-Flu+COVID19 Ag, showed an acceptable sensitivity and sufficient specificity for SARS-CoV-2 detection, especially using nasopharyngeal sample collected from symptomatic patients.

18 May 2021 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
YKYoshihiko Kiyasu
Yoshihiko Kiyasu
YAYusaku Akashi
Yusaku Akashi
ASAkio Sugiyama
Akio Sugiyama
YTYuto Takeuchi
Yuto Takeuchi
SNShigeyuki Notake
Shigeyuki Notake
HSHiromichi Suzuki
Hiromichi Suzuki

7 April 2022 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
YAYusaku Akashi
Yusaku Akashi
MHMichiko Horie
Michiko Horie
JKJunichi Kiyotaki
Junichi Kiyotaki
YTYuto Takeuchi
Yuto Takeuchi
KTKenichi Togashi
Kenichi Togashi
HSHiromichi Suzuki
Hiromichi Suzuki

1 October 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YKYoshihiko Kiyasu
Yoshihiko Kiyasu
YTYuto Takeuchi
Yuto Takeuchi
YAYusaku Akashi
Yusaku Akashi
DKDaisuke Kato
Daisuke Kato
MKMiwa Kuwahara
Miwa Kuwahara
HSHiromichi Suzuki
Hiromichi Suzuki

1 October 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
YKYoko Kurihara
Yoko Kurihara
YKYoshihiko Kiyasu
Yoshihiko Kiyasu
YAYusaku Akashi
Yusaku Akashi
YTYuto Takeuchi
Yuto Takeuchi
KNKenji Narahara
Kenji Narahara
HSHiromichi Suzuki
Hiromichi Suzuki
Rapid antigen tests are convenient for diagnosing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, they have lower sensitivities than nucleic acid amplification tests. In this study, we evaluated the diagnostic performance of Quick Chaser® Auto SARS-CoV-2, a novel digital immunochromatographic assay that is expected to have higher sensitivity than conventional antigen tests. A prospective observational study was conducted between February 8 and March 24, 2021. We simultaneously obtained two nasopharyngeal samples, one for evaluation with the QuickChaser® Auto SARS-CoV-2 antigen test and the other for assessment with reverse transcription PCR (RT-PCR), considered the gold-standard reference test. The limit of detection (LOD) of the new antigen test was compared with those of four other commercially available rapid antigen tests. A total of 1401 samples were analyzed. SARS-CoV-2 was detected by reference RT-PCR in 83 (5.9%) samples, of which 36 (43.4%) were collected from symptomatic patients. The sensitivity, specificity, positive predictive value, and negative predictive value were 74.7% (95% confidence interval (CI): 64.0–83.6%), 99.8% (95% CI: 99.5–100%), 96.9% (95% CI: 89.2–99.6%), and 98.4% (95% CI: 97.6–99.0%), respectively. When limited to samples with a cycle threshold (Ct) < 30 or those from symptomatic patients, the sensitivity increased to 98.3% and 88.9%, respectively. The QuickChaser® Auto SARS-CoV-2 detected 34–120 copies/test, which indicated greater sensitivity than the other rapid antigen tests. QuickChaser® Auto SARS-CoV-2 showed sufficient sensitivity and specificity in clinical samples of symptomatic patients. The sensitivity was comparable to RT-PCR in samples with Ct < 30.